A Study to Assess the Safety and Efficacy of ASP1650, a Monoclonal Antibody Targeting Claudin 6 (CLDN6), in Male Subjects with Incurable Platinum Refractory Germ Cell Tumors

Trial Identifier: 1650-CL-0201
Sponsor: Astellas Pharma Global Development, Inc.
Start Date: March 2019
Primary Completion Date: October 2020
Condition: Cancer - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
United States of America, IN Indianapolis, IN, United States of America, 46202
United States of America, NY New York, NY, United States of America, 10065
United States of America, PA Philadelphia, PA, United States of America, 19104